Chronic Radiation Dermatitis Clinical Trial
Official title:
Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study
| Verified date | November 2023 |
| Source | Massachusetts General Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Radiotherapy, an essential modality in cancer treatment, frequently induces a fibrotic process in the skin which can lead to increased risk of malignancy, poor wound healing, pain and limitation of movement, and permanent loss of skin appendages with hyper/hypopigmentation, decreased sweating and xerosis, posing significant cosmetic and quality of life issues. Advances in laser therapy has led to the use of fractional laser treatment (FLT) to treat fibrosis associated with in hypertrophic scars and morphea, leading to tissue repair, scar remodeling. The investigators propose a pilot clinical study to test the hypothesis that FLT can normalize the fibrotic process and induce normal scar remodeling in patients affected by chronic radiation injury. Understanding and correcting this underlying fibrotic process can help restore normal skin functions in patients affected with chronic radiation dermatitis (RD) and other debilitating fibrotic diseases in dermatology such as scleroderma, morphea, or nephrogenic systemic fibrosis.
| Status | Active, not recruiting |
| Enrollment | 12 |
| Est. completion date | August 2026 |
| Est. primary completion date | August 2025 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion Criteria: 1. Healthy males and females between 18 and 80 years of age with radiation-induced fibrosis and depigmentation. The fibrosis must have occurred at least 1 year prior to the date of enrollment. 2. Having suitable areas of treatment: All wounds in the area of interest must be closed for at least two months. The scars must be deemed stable for a period of 3 months or have a suitable contralateral control before initiation of treatment. This will be determined by objective measurements of scar erythema, pliability, induration, thickness at enrollment and again at 3 months; 3. Fitzpatrick skin types I-VI; 4. Able and willing to comply with all visit, treatment and evaluation schedules and requirements; 5. Able to understand and provide written informed consent; 6. Pregnant woman can be included because study involves local intervention, no new drugs. Exclusion Criteria: 1. Active tanning, including the use of tanning booths, during the course of the study; 2. Prior skin treatment with laser or other devices in the treated area within three months of initial treatment or during the course of the study; 3. Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists; 4. History of collagen vascular disease; 5. Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment; 6. History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications; 7. Having any form of active cancer at the time of enrollment and during the course of the study; 8. Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); Mentally incompetent, prisoner or evidence of active substance or alcohol abuse; 9. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study; 10. If it is determined that the contracture is due to a deeper process involving the muscles, ligaments or bones. 11. Patient on chemotherapy (but not tamoxifen or other things that affect wound healing) and also active XRT 12. Participation in another interventional study with potential exposure to an investigational drug within past 30 days |
| Country | Name | City | State |
|---|---|---|---|
| United States | Wellman Center for Photomedicine, Massachusetts General Hospital | Boston | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Massachusetts General Hospital |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Improvement in fibrosis (% reduction in fibrosis surface area) compared to controlled sites | The primary end point is % reduction of the fibrosis surface area compared to control sites at 6-12 months. | 6-12 months | |
| Secondary | Adverse events | Measurement adverse events (infection, scarring, ulceration, excessive bleeding, poor wound healing) | 2 years |